Terms: = Liver cancer AND MET, RCCP2, 4233, ENSG00000105976, P08581, HGFR, AUTS9
2582 results:
1. Robotic sectionectomy versus robotic hemihepatectomy for anatomic liver resection: a comparative analysis of perioperative outcomes.
Birgin E; Heibel M; Téoule P; Reißfelder C; Rahbari NN
J Robot Surg; 2024 May; 18(1):197. PubMed ID: 38703346
[TBL] [Abstract] [Full Text] [Related]
2. Anti-PD-1 antibody in combination with radiotherapy as first-line therapy for unresectable intrahepatic cholangiocarcinoma.
Zhu M; Jin M; Zhao X; Shen S; Chen Y; Xiao H; Wei G; He Q; Li B; Peng Z
BMC Med; 2024 Apr; 22(1):165. PubMed ID: 38637772
[TBL] [Abstract] [Full Text] [Related]
3. The role of piRNAs in predicting and prognosing in cancer: a focus on piRNA-823 (a systematic review and meta-analysis).
Taghizadeh M; Jafari-Koshki T; Jafarlou V; Raeisi M; Alizadeh L; Roosta Y; Matin S; Jabari R; Sur D; Karimi A
BMC Cancer; 2024 Apr; 24(1):484. PubMed ID: 38627675
[TBL] [Abstract] [Full Text] [Related]
4. Management of sotorasib-related adverse events and hepatotoxicities following anti-PD-(L)1 therapy: Experience with sotorasib in two French anti-cancer centers and practical guidance proposal.
Chour A; Basse C; Lebossé F; Bonte PE; Girard N; Duruisseaux M
Lung Cancer; 2024 May; 191():107789. PubMed ID: 38614068
[TBL] [Abstract] [Full Text] [Related]
5. The Comparison of Serum Interleukin-8 Levels Based on Severity of liver Cirrhosis.
Rey I; Effendi-Ys R; Sukatendel K
Med Arch; 2024; 78(2):92-94. PubMed ID: 38566873
[TBL] [Abstract] [Full Text] [Related]
6. Atezolizumab plus modified docetaxel, cisplatin, and fluorouracil as first-line treatment for advanced anal cancer (SCARCE C17-02 PRODIGE 60): a randomised, non-comparative, phase 2 study.
Kim S; Ghiringhelli F; de la Fouchardière C; Evesque L; Smith D; Badet N; Samalin E; Lopez-Trabada Ataz D; Parzy A; Desramé J; Baba Hamed N; Buecher B; Tougeron D; Bouché O; Dahan L; Chibaudel B; El Hajbi F; Mineur L; Dubreuil O; Ben Abdelghani M; Pecout S; Bibeau F; Herfs M; Garcia ML; Meurisse A; Vernerey D; Taïeb J; Borg C
Lancet Oncol; 2024 Apr; 25(4):518-528. PubMed ID: 38547895
[TBL] [Abstract] [Full Text] [Related]
7. c-met pathway in human malignancies and its targeting by natural compounds for cancer therapy.
Mohan CD; Shanmugam MK; Gowda SGS; Chinnathambi A; Rangappa KS; Sethi G
Phytomedicine; 2024 Jun; 128():155379. PubMed ID: 38503157
[TBL] [Abstract] [Full Text] [Related]
8. First-in-human study of JNJ-67571244, a CD33 × CD3 bispecific antibody, in relapsed/refractory acute myeloid leukemia and myelodysplastic syndrome.
Narayan R; Piérola AA; Donnellan WB; Yordi AM; Abdul-Hay M; Platzbecker U; Subklewe M; Kadia TM; Alonso-Domínguez JM; McCloskey J; Bradford K; Curtis M; Daskalakis N; Guttke C; Safer K; Hiebert B; Murphy J; Li X; Duchin K; Esteban D
Clin Transl Sci; 2024 Mar; 17(3):e13742. PubMed ID: 38494922
[TBL] [Abstract] [Full Text] [Related]
9. Drug-Eluting Bead Transarterial Chemoembolization for Hepatocellular Carcinoma: The Effectiveness of Different Particle Sizes in Downstaging and Bridging in Living Donor liver Transplantation.
Lim WX; Sim KS; Chen CL; Ou HY; Yu CY; Cheng YF
Transplant Proc; 2024 Apr; 56(3):596-601. PubMed ID: 38472083
[TBL] [Abstract] [Full Text] [Related]
10. A comprehensive analysis of liver safety across zibotentan oncology trials: knowledge of the past offers new perspectives on the present.
Fettiplace A; Matis-Mitchell S; Molodetskyi O; Söderbergh M; Oscarsson J; Lin M; Ravikiran S; Billger M; Ambery P
Expert Opin Drug Saf; 2024 Apr; 23(4):477-486. PubMed ID: 38469902
[TBL] [Abstract] [Full Text] [Related]
11. Factors affecting the compliance of hepatocellular carcinoma screening among high-risk populations: A systematic review and meta-analysis.
Feng GH; Yue QQ; Zhao KH; Peng T; Tang T; Sun YX; Meng XR; Huang LL; Zeng X; Zeng Y
Public Health Nurs; 2024; 41(3):476-486. PubMed ID: 38468509
[TBL] [Abstract] [Full Text] [Related]
12. The phosphatidylserine targeting antibody bavituximab plus pembrolizumab in unresectable hepatocellular carcinoma: a phase 2 trial.
Hsiehchen D; Beg MS; Kainthla R; Lohrey J; Kazmi SM; Khosama L; Maxwell MC; Kline H; Katz C; Hassan A; Kubota N; Siglinsky E; Pillai AK; Youssoufian H; Mockbee C; Culm K; Uhlik M; Benjamin L; Brekken RA; Ahn C; Singal AG; Zhu H; Hoshida Y; Yopp AC
Nat Commun; 2024 Mar; 15(1):2178. PubMed ID: 38467639
[TBL] [Abstract] [Full Text] [Related]
13. Laparoscopic liver resection versus radiofrequency ablation for caudate lobe solitary hepatocellular carcinoma: A propensity score matching study.
Wang Z; Ouyang J; Jia B; Zhou Y; Yang Y; Li X; Li Q; Zhou J
Cancer Med; 2024 Feb; 13(4):e7068. PubMed ID: 38457235
[TBL] [Abstract] [Full Text] [Related]
14. Detection of hepatocellular carcinoma methylation markers in salivary DNA.
Mezzacappa C; Wang Z; Lu L; Risch H; Taddei T; Yu H
Biosci Rep; 2024 Mar; 44(3):. PubMed ID: 38457142
[TBL] [Abstract] [Full Text] [Related]
15. Multiregion WES of metastatic pancreatic neuroendocrine tumors revealed heterogeneity in genomic alterations, immune microenvironment and evolutionary patterns.
Jiang Y; Dong YH; Zhao SW; Liu DY; Zhang JY; Xu XY; Chen H; Chen H; Jin JB
Cell Commun Signal; 2024 Mar; 22(1):164. PubMed ID: 38448900
[TBL] [Abstract] [Full Text] [Related]
16. Durvalumab Plus Gemcitabine and Cisplatin in Patients with Advanced Biliary Tract cancer: An Exploratory Analysis of Real-World Data.
Olkus A; Tomczak A; Berger AK; Rauber C; Puchas P; Wehling C; Longerich T; Mehrabi A; Chang DH; Liermann J; Schäfer S; Pfeiffenberger J; Jäger D; Michl P; Springfeld C; Dill MT
Target Oncol; 2024 Mar; 19(2):213-221. PubMed ID: 38416377
[TBL] [Abstract] [Full Text] [Related]
17. Incidence and Risk Factor of Hepatocellular Carcinoma Recurrence After liver Transplant: Results From a Single Clinic.
Bolkvadze R; Kashibadze K; Nakashidze M; Mikeladze L; Beridze D; Beridze S
Exp Clin Transplant; 2024 Jan; 22(Suppl 1):256-262. PubMed ID: 38385408
[TBL] [Abstract] [Full Text] [Related]
18. Utilizing physician modified fenestration on the castor branched stent technique for reconstruction of an isolated left vertebral artery on the aortic arch.
Luo ZR; Li SL; Chen LW; Huang RD
Sci Rep; 2024 Feb; 14(1):4051. PubMed ID: 38374192
[TBL] [Abstract] [Full Text] [Related]
19. Comparison of tumor response and outcomes of patients with hepatocellular carcinoma after multimodal treatment including immune checkpoint inhibitors - a systematic review and meta-analysis.
Dawood ZS; Brown ZJ; Alaimo L; Lima HA; Shaikh C; Katayama ES; Munir MM; Moazzam Z; Endo Y; Woldesenbet S; Pawlik TM
HPB (Oxford); 2024 May; 26(5):618-629. PubMed ID: 38369433
[TBL] [Abstract] [Full Text] [Related]
20. Development of a short-term nutritional risk prediction model for hepatocellular carcinoma patients: a retrospective cohort study.
Yu J; Lam SK; He L; Wang P; Cao Y
Sci Rep; 2024 Feb; 14(1):3921. PubMed ID: 38365922
[TBL] [Abstract] [Full Text] [Related]
[Next]
